<unk>  is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate and for the treatment of male pattern hair loss (androgenetic alopecia) in men. Enlarged prostate Physicians sometimes prescribe<unk>  for the treatment of benign prostatic hyperplasia (BPH), informally known as an enlarged prostate.<unk>  may improve the symptoms associated with BPH such as difficulty urinating, getting up during the night to urinate, hesitation at the start and end of urination, and decreased urinary flow. It provides less symptomatic relief than alpha-1 blockers such as tamsulosin and symptomatic relief is slower in onset (six months or more of treatment with<unk>  may be required to determine the therapeutic results of treatment). Symptomatic benefits are mainly seen in those with prostate volume > 40 cm3. In long-term studies<unk>  but not alpha-1 inhibitors reduce the risk of acute urinary retention (−57% at 4 years) and the need for surgery (−54% at 4 years). If the drug is discontinued, any therapeutic benefits are reversed within about 6–8 months. Scalp hair loss<unk>  is also used to treat male pattern baldness (androgenic alopecia) in men, a condition that develops in up to 80% of Caucasian men. In the United States,<unk>  and minoxidil are the only two FDA approved drugs for the treatment of male pattern hair loss as of 2017. Treatment with<unk>  slows further hair loss and provides about 30% improvement in hair loss after six months of treatment, with effectiveness persisting as long as the drug is taken. Taking<unk>  leads to a reduction in scalp and serum DHT levels; by lowering scalp levels of DHT,<unk>  can maintain or increase the amount of terminal hairs in the anagen phase by inhibiting and sometimes reversing miniaturization of the hair follicle.<unk>  is most effective on the crown but can reduce hair loss in all areas of the scalp.<unk>  has also been tested for pattern hair loss in women; however, the results were no better than placebo.<unk>  is less effective in the treatment of scalp hair loss than dutasteride. Prostate cancer In males over 55 years old<unk>  decreases the risk of low-grade prostate cancer but may increase the risk of high-grade prostate cancer and has no effect on overall survival. A 2010 review found a 25% reduction in the risk of prostate cancer with 5α-reductase inhibitor. A follow-up study of the Medicare claims of participants in a 10-year Prostate Cancer Prevention Trial suggests the reduction in prostate cancer is maintained even after discontinuation of treatment. However, 5α-reductase inhibitors have been found to increase the risk of developing certain rare but aggressive forms of prostate cancer (27% risk increase), although not all studies have observed this. No impact of 5-α-reductase inhibitor on survival has been found in people with prostate cancer. Excessive hair growth<unk>  has been found to be effective in the treatment of hirsutism (excessive facial and/or body hair growth) in women. In a study of 89 women with hyperandrogenism due to persistent adrenarche syndrome,<unk>  produced a 93% reduction in facial hirsutism and a 73% reduction bodily hirsutism after 2 years of treatment. Other studies using<unk>  for hirsutism have also found it to be clearly effective. Transgender hormone therapy<unk>  is sometimes used in hormone replacement therapy for transgender women due to its antiandrogenic effects, in combination with a form of estrogen. However, little clinical research of<unk>  use for this purpose has been conducted and evidence of safety or efficacy is limited. Moreover, caution has been recommended when prescribing<unk>  to transgender women, as<unk>  may be associated with side effects such as depression, anxiety, and suicidal ideation, symptoms that are particularly prevalent in the transgender population and in others at high risk already.
Finasteride
Dutasteride
Alclometasone
Tadalafil
Tamsulosin
Dutasteride/tamsulosin
Cyproterone acetate
Ingenol mebutate